A Phase 0 clinical study with TTX-MC138

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 24 Aug 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Aug 2023 Status changed from not yet recruiting to recruiting, according to a TransCode Therapeutics media release.
23 Aug 2023 According to a TransCode Therapeutics media release, company announced the dosing of the first subject.
05 Jul 2023 According to a TransCode Therapeutics media release, in Apr 2023 the company has received institutional review board (IRB) approval from Dana Farber Cancer Center in Boston, MA, to enroll and dose patients in this Phase 0 trial, which is expect to commence shortly.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com